Literature DB >> 31248877

ETV6-related thrombocytopenia and leukemia predisposition.

Jorge Di Paola1, Christopher C Porter2.   

Abstract

Germ line mutations in ETV6 are responsible for a familial thrombocytopenia and leukemia predisposition syndrome. Thrombocytopenia is almost completely penetrant and is usually mild. Leukemia is reported in ∼30% of carriers and is most often B-cell acute lymphoblastic leukemia. The mechanisms by which ETV6 dysfunction promotes thrombocytopenia and leukemia remain unclear. Care for individuals with ETV6-related thrombocytopenia and leukemia predisposition includes genetic counseling, treatment or prevention of excessive bleeding and surveillance for the development of hematologic malignancy.
© 2019 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31248877      PMCID: PMC6706811          DOI: 10.1182/blood.2019852418

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  TEL/AML1 shows dominant-negative effects over TEL as well as AML1.

Authors:  Hisako Gunji; Kazuo Waga; Fumihiko Nakamura; Kazuhiro Maki; Ko Sasaki; Yuichi Nakamura; Kinuko Mitani
Journal:  Biochem Biophys Res Commun       Date:  2004-09-17       Impact factor: 3.575

2.  Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Kajsa Paulsson; Erik Forestier; Henrik Lilljebjörn; Jesper Heldrup; Mikael Behrendtz; Bryan D Young; Bertil Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  Germline deletion of ETV6 in familial acute lymphoblastic leukemia.

Authors:  Evadnie Rampersaud; David S Ziegler; Ilaria Iacobucci; Debbie Payne-Turner; Michelle L Churchman; Kasmintan A Schrader; Vijai Joseph; Kenneth Offit; Katherine Tucker; Rosemary Sutton; Meera Warby; Georgia Chenevix-Trench; David G Huntsman; Maria Tsoli; R Scott Mead; Chunxu Qu; Vasiliki Leventaki; Gang Wu; Charles G Mullighan
Journal:  Blood Adv       Date:  2019-04-09

4.  Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.

Authors:  Michelle L Churchman; Maoxiang Qian; Geertruy Te Kronnie; Ranran Zhang; Wenjian Yang; Hui Zhang; Tobia Lana; Paige Tedrick; Rebekah Baskin; Katherine Verbist; Jennifer L Peters; Meenakshi Devidas; Eric Larsen; Ian M Moore; Zhaohui Gu; Chunxu Qu; Hiroki Yoshihara; Shaina N Porter; Shondra M Pruett-Miller; Gang Wu; Elizabeth Raetz; Paul L Martin; W Paul Bowman; Naomi Winick; Elaine Mardis; Robert Fulton; Martin Stanulla; William E Evans; Mary V Relling; Ching-Hon Pui; Stephen P Hunger; Mignon L Loh; Rupert Handgretinger; Kim E Nichols; Jun J Yang; Charles G Mullighan
Journal:  Cancer Cell       Date:  2018-04-19       Impact factor: 31.743

5.  TEL, a putative tumor suppressor, modulates cell growth and cell morphology of ras-transformed cells while repressing the transcription of stromelysin-1.

Authors:  R Fenrick; L Wang; J Nip; J M Amann; R J Rooney; J Walker-Daniels; H C Crawford; D L Hulboy; M S Kinch; L M Matrisian; S W Hiebert
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 6.  Inherited platelet disorders : Management of the bleeding risk.

Authors:  Arnaud Dupuis; Christian Gachet
Journal:  Transfus Clin Biol       Date:  2018-08-01       Impact factor: 1.406

7.  BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros.

Authors:  Charles G Mullighan; Christopher B Miller; Ina Radtke; Letha A Phillips; James Dalton; Jing Ma; Deborah White; Timothy P Hughes; Michelle M Le Beau; Ching-Hon Pui; Mary V Relling; Sheila A Shurtleff; James R Downing
Journal:  Nature       Date:  2008-04-13       Impact factor: 49.962

Review 8.  Genetic Counselor Recommendations for Cancer Predisposition Evaluation and Surveillance in the Pediatric Oncology Patient.

Authors:  Harriet Druker; Kristin Zelley; Rose B McGee; Sarah R Scollon; Wendy K Kohlmann; Katherine A Schneider; Kami Wolfe Schneider
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

9.  Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia.

Authors:  Leila Noetzli; Richard W Lo; Walter H A Kahr; Christopher C Porter; Jorge Di Paola; Alisa B Lee-Sherick; Michael Callaghan; Patrizia Noris; Anna Savoia; Madhvi Rajpurkar; Kenneth Jones; Katherine Gowan; Carlo Balduini; Alessandro Pecci; Chiara Gnan; Daniela De Rocco; Michael Doubek; Ling Li; Lily Lu; Richard Leung; Carolina Landolt-Marticorena; Stephen Hunger; Paula Heller; Arthur Gutierrez-Hartmann; Liang Xiayuan; Fred G Pluthero; Jesse W Rowley; Andrew S Weyrich
Journal:  Nat Genet       Date:  2015-03-25       Impact factor: 38.330

10.  Common genetic variation in ETV6 is associated with colorectal cancer susceptibility.

Authors:  Meilin Wang; Dongying Gu; Mulong Du; Zhi Xu; Suzhan Zhang; Lingjun Zhu; Jiachun Lu; Rui Zhang; Jinliang Xing; Xiaoping Miao; Haiyan Chu; Zhibin Hu; Lei Yang; Cuiju Tang; Lei Pan; Haina Du; Jian Zhao; Jiangbo Du; Na Tong; Jielin Sun; Hongbing Shen; Jianfeng Xu; Zhengdong Zhang; Jinfei Chen
Journal:  Nat Commun       Date:  2016-05-05       Impact factor: 14.919

View more
  10 in total

Review 1.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

Review 2.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

Review 3.  Inherited Platelet Disorders: An Updated Overview.

Authors:  Verónica Palma-Barqueros; Nuria Revilla; Ana Sánchez; Ana Zamora Cánovas; Agustín Rodriguez-Alén; Ana Marín-Quílez; José Ramón González-Porras; Vicente Vicente; María Luisa Lozano; José María Bastida; José Rivera
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

4.  ETV6-ACSL6 fusion gene in myeloid neoplasms: clinical spectrum, current practice, and outcomes.

Authors:  Xia Wu; Hao Cai; Yu Qiu; Jian Li; Dao-Bin Zhou; Xin-Xin Cao
Journal:  Orphanet J Rare Dis       Date:  2020-07-28       Impact factor: 4.123

Review 5.  Inherited thrombocytopenias: history, advances and perspectives.

Authors:  Alan T Nurden; Paquita Nurden
Journal:  Haematologica       Date:  2020-06-11       Impact factor: 9.941

Review 6.  Clonal hematopoietic mutations linked to platelet traits and the risk of thrombosis or bleeding.

Authors:  Alicia Veninga; Ilaria De Simone; Johan W M Heemskerk; Hugo Ten Cate; Paola E J van der Meijden
Journal:  Haematologica       Date:  2020-06-18       Impact factor: 9.941

Review 7.  Prevalence and natural history of variants in the ANKRD26 gene: a short review and update of reported cases.

Authors:  Hrushikesh Vyas; Ahmad Alcheikh; Gillian Lowe; William S Stevenson; Neil V Morgan; David J Rabbolini
Journal:  Platelets       Date:  2022-05-19       Impact factor: 4.236

8.  ETV6: A Candidate Gene for Predisposition to "Blend Pedigrees"? A Case Report from the NEXT-Famly Clinical Trial.

Authors:  Simona Bernardi; Mirko Farina; Camilla Zanaglio; Federica Cattina; Nicola Polverelli; Francesca Schieppati; Federica Re; Chiara Foroni; Michele Malagola; Andrew J Dunbar; Domenico Russo
Journal:  Case Rep Hematol       Date:  2020-01-11

9.  ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes.

Authors:  Marlie H Fisher; Gregory D Kirkpatrick; Brett Stevens; Courtney Jones; Michael Callaghan; Madhvi Rajpurkar; Joy Fulbright; Megan A Cooper; Jesse Rowley; Christopher C Porter; Arthur Gutierrez-Hartmann; Kenneth Jones; Craig Jordan; Eric M Pietras; Jorge Di Paola
Journal:  JCI Insight       Date:  2020-09-17

10.  The role of E26 transformation-specific variant transcription factor 5 in colorectal cancer cell proliferation and cell cycle progression.

Authors:  Yi Peng; Haoran Feng; Changgang Wang; Zijia Song; Yaqi Zhang; Kun Liu; Xi Cheng; Ren Zhao
Journal:  Cell Death Dis       Date:  2021-04-30       Impact factor: 8.469

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.